Carvedilol Versus Controlled-Release Metoprolol for Elderly Veterans with Heart Failure

    loading  Checking for direct PDF access through Ovid

Abstract

OBJECTIVES

To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged ≥65) and to compare the time to first hospitalization or death.

DESIGN

Retrospective cohort.

SETTING

Veterans Health Administration (VHA) nationwide healthcare system.

SUBJECTS

Veterans enrolled in fee-for-service Medicare that had a VHA diagnosis of heart failure and a first prescription for carvedilol (n=17,429) or CR metoprolol (n=8,683) between October 1999 and September 2003.

MEASUREMENTS

Prescribed daily doses and CR metoprolol-to-carvedilol hazard ratios (HRs) estimated using Cox regression within strata defined according to propensity to prescribe carvedilol.

RESULTS

After several months, the majority of prescribed doses in both cohorts were less than 50% of target doses. The risk-adjusted HR was 0.99 (95% confidence interval=0.96–1.03) for hospitalization or death and 0.91 (0.85–0.96) for death alone.

CONCLUSION

Doses of beta-blockers being prescribed to predominantly elderly veterans with heart failure were much lower than proven doses. Whether efforts to increase doses can improve the effectiveness of beta-blocker therapy warrants further study. At the prescribed doses, CR metoprolol was associated with better survival than carvedilol, although unmeasured confounding variables might explain the observed difference in survival.

Related Topics

    loading  Loading Related Articles